Form 4: EyePoint Pharmaceuticals Director Wendy F. Dicicco Reports Stock Option Grant
SEC Form 4
Director Wendy F. Dicicco reports the acquisition of stock options in EyePoint Pharmaceuticals.
Summary
- On January 3, 2025, Wendy F. Dicicco, a director of EyePoint Pharmaceuticals, Inc., acquired 40,000 stock options.
- The options have an exercise price of $8.26.
- The options become exercisable on January 3, 2026, and expire on January 3, 2035.
- Following the transaction, Ms. Dicicco directly owns 40,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. It suggests alignment of interests but doesn't provide specific financial performance information.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of transaction: Stock options acquired |
| 01/03/2026 | Date exercisable: Stock options become exercisable |
| 01/03/2035 | Expiration date: Stock options expire |
| 01/07/2025 | Date of report filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.